Objective-To determine whether efferent muscle sympathetic nerve activity diminishes in subjects with dilated cardiomyopathy who improve after long term treatment with metoprolol. Methods-Microneurographic, echocardiographic, plethysmographic, and neurohumoral data were obtained immediately before and 20 months after the addition of a1 blockade in seven subjects with idiopathic dilated cardiomyopathy with clinical deterioration despite conventional treatment. Results-Six subjects (three men, three women, aged 24-62 years) were restudied after a mean (SEM) of 20 (2.4) months treatment with metoprolol (45.8 (2.6) mgld). Long term treatment was asso-431 on January 16, 2020 by guest. Protected by copyright.
ciated with decreases in left ventricular end diastolic and end systolic diameter (P < 0.005), left ventricular mass index (P < 0*05), and atrial natriuretic factor (P < 0.05), and increases in fractional shortening (P < 0.05) and mean blood pressure (P < 0.05). There was a 50% reduction in peroneal muscle sympathetic nerve activity (from 49*2 (10*1) to 24*5 (4.7) bursts/min; (P < 0.005) and a 62% decrease in calf vascular resistance (from 56'2 to 21-2 (5.7) units; P < 0.005). This reduction in pulse synchronous nerve activity was not simply a function of bradycardia (heart rate fell from 94-2 (4.6) to 62*8 (5.7) beats/min; P < 0.005) since muscle sympathetic burst incidence also decreased (from 51 (8.7) to 37-5 (5.2) bursts/100 heart beats; P < 0.05). Similar haemodynamic improvement was observed in the seventh subject, who was switched to sotalol 200 mg/d and restudied after 20 months, but burst frequency was 50%/0 higher and calf vascular resistance 93% higher. Conclusions-Muscle sympathetic nerve activity and calf vascular resistance decrease in patients with dilated cardiomyopathy who improve after long term treatment with metoprolol. Inhibition of central sympathetic outflow may be one mechanism by which metoprolol benefits such subjects. (Br HeartJf 1995; 74:431-436) Keywords: metoprolol; dilated cardiomyopathy; sympathetic nerve activity Sympathetic nervous system activation is an important marker for adverse outcome in congestive heart failure.' Although the mechanisms responsible for this disturbance have not been fully elucidated,2A its adverse consequences for the failing myocardium have been well documented.357
In 1975 Waagstein and coworkers reported symptomatic and haemodynamic improvement after short term ,l adrenoceptor blockade in seven patients with idiopathic dilated cardiomyopathy.8 These observations provided the impetus for subsequent studies of chronic ,6 adrenoceptor blockade in selected patients. Recently, a placebo controlled multicentre trial reported a favourable impact of metoprolol on symptoms, cardiac function, and disease progression in this condition.9
Reversal of ,B adrenoceptor downregulation or uncoupling are two of the presumed benefits of chronic fi adrenoceptor blockade in congestive heart failure.'0 Its effects on central sympathetic outflow are not known.
fi Adrenoceptor antagonists might oppose the actions of catecholamines on postjunctional adrenoceptors in the heart and the peripheral circulation without attenuating sympathetic outflow to heart, kidney, and peripheral vasculature. Indeed, by reducing discharge from cardiac mechanoreceptors with inhibitory vagal afferents, the negative inotropic properties of fi adrenoceptor blockers might cause a reflex increase in sympathetic nerve traffic." Alternatively, fi adrenergic antagonists might attenuate sympathetic drive to the heart and periphery through a central or reflex action. Wallin et at"2 observed reductions in both blood pressure and muscle sympathetic nerve burst frequency in hypertensive subjects restudied after four months of oral metoprolol. Noradrenaline release across the failing human heart may be attenuated by carvedilol."3 We undertook this study to test the hypothesis that efferent muscle sympathetic nerve activity diminishes in those subjects with dilated cardiomyopathy who improve after long term treatment with metoprolol.
Methods

SUBJECTS
Seven subjects with idiopathic dilated cardiomyopathy (four men, three women, mean (SEM) age 37 (5) years, range 24-62 years), were referred for this study by their attending cardiologists in anticipation of starting fi adrenergic blockade treatment with metopro- Subjects restudied on metoprolol   1  29  F  48  1-454  II  15  ADFC  88  51  103  66  2  28  F  65  1-714  III  16  ADFH  89  53  81  48  3  62  F  62  1-702  III  14  ADFC  97  72  88  37  4  36  M  95  2-174  II  18  AC  95  49  84  20  5  34  M  82  2-023  II  10  ADFC  114  63  108  89  6  24  M  73  1 lol. All subjects had been admitted to hospital for the management of progressive congestive heart failure and met the following criteria: left ventricular ejection fraction < 25%, marked global hypokinesia, and a short axis left ventricular end diastolic dimension (LVDD) of 60 mm or more. Coronary artery disease and active myocarditis were excluded by coronary angiography and endocardial biopsy. None had concomitant medical conditions that might otherwise alter sympathetic nerve activity. All subjects suffered progressive clinical deterioration despite sodium restriction, and several months (mean 7 (3), range 1-22 months) of chronic treatment with diuretics (n = 4), digitalis (n = 6), and angiotensin converting enzyme (ACE) inhibitors (n = 6). One subject (No 6) was unable to tolerate ACE inhibition because of hypotension. All were on anticoagulants (table 1) . At entry, mean reported New York Heart Association functional class was 2-7 (0 3). Their ejection fractions, as assessed by radionuclide ventriculography, ranged from 10% to 23% (mean 15 (2)%). The decision to start metoprolol was made independently by the patients' own cardiologists. . Sympathetic nerve activity in this subject fellfrom 89 to 41 bursts/min. and heart rate was derived from lead II of the electrocardiogram. Calf blood flow (ml/min/100 ml of calf volume) was estimated by venous occlusion plethysmography."4 Calf vascular resistance (expressed as resistance units) was calculated as the quotient of mean arterial pressure divided by the average of four to six measures of calf blood flow. Left ventricular dimensions were determined by M mode echocardiography (Ultramark 8; Advanced Technology Laboratories) with subjects in the left lateral position. Left ventricular mass and mass index were calculated using the formula of Devereux and Reichek.'5 Multiunit recordings of post-ganglionic muscle sympathetic activity were obtained from the peroneal nerve. 16 Sympathetic activity was expressed as bursts/min (burst frequency) and bursts/100 cardiac cycles (burst incidence). The mean interobserver variability arising from visual evaluation of the microneurographic record in our laboratory is Reductions in muscle sympathetic nerve activity after long term metoprololfor dilated cardiomyopathy: preliminary observations by our institutional human subjects review committee. ,6 ADRENOCEPTOR BLOCKADE Metoprolol was started by the attending cardiologist at doses as low as 5 mg daily and gradually increased as tolerated. All subjects but one (subject No 3) were admitted to hospital for this purpose. Six subjects (Nos 1-6) were restudied after an average of 20 months on between 37-5 and 50 mg of metoprolol daily (final average dose, 45-8 (2-6) mg/d) (table 1). One subject (No 7 in table 1) was able to tolerate metoprolol 50 mg orally twice daily but because of non-sustained ventricular tachycardia was switched soon after to sotalol 200 mg/d and restudied while on that drug 20 months after his first study.
STATISTICAL PROCEDURES
Data were analysed with Systat 5-2 (Systat Intelligent Software) and are presented as mean (SEM), unless stated otherwise. Paired t tests were applied to compare pre-treatment and post-treatment values. Figure 2 Plots of heart rate and mean arterial blood pressure immediately before addition of metoprolol (time 1) and after long term treatment (time 2). Average heart rate was significantly lower (P < 0O005), and average mean arterial pressure significantly higher (P < 005) after ,B blockade.
Results
Mean data from the six subjects restudied while on metoprolol (table 1), used to assess the effects of long term treatment, will be referred to as the group mean. Group means for haemodynamic, echocardiographic, and neurohumonal variables before metoprolol and on metoprolol are presented in table 2. Individual data points are presented in figs 2-4.
HAEMODYNAMIC CHANGES
Long term metoprolol treatment was associated with increases in systolic blood pressure (P < 0 05) and mean blood pressure (P < 0 05) and decreases in heart rate (P < 0'005) (table 2). In five subjects calf blood flow increased threefold (P < 0 05), and there was a corresponding decrease in calf vascular resistance (P < 0 005) (fig 4) . In the sixth subject calf blood flow was undetectable at baseline by this technique and it was 1-5 ml/min/100 ml calf volume on restudy. There was a similar increase in blood pressure and decrease in heart rate in the one subject restudied on sotalol ( fig 3) . These changes were associated with significant increases in fractional shortening. Calculated left ventricular mass and mass index decreased in all six subjects. There were qualitatively similar changes in these echocardiographic variables in the sotalol treated subjects-for example, fractional shortening increased from 13% to 27%.
NEURAL AND HORMONAL CHANGES
Muscle sympathetic nerve burst frequency fell in all six metoprolol treated subjects (P < 0 005) (table 2, fig 4) . These changes in pulse synchronous sympathetic outflow remained significant even when expressed as burst incidence, by adjusting for reductions in heart rate (P < 0 005). There were corresponding reductions in plasma noradrenaline concentrations (P 0 07) and plasma atrial natriuretic factor (P < 0 05) (table 2; fig 4) . There was no relation between the relative reduction in muscle sympathetic burst incidence and the initial heart rate of these subjects (r = 0-6, P-0 18; n = 6). By contrast, sympathetic nerve burst frequency increased 50% in the subject restudied on sotalol (from 22 to 33 bursts/min) and burst incidence by 81% (from 26 to 47 bursts/100 heart beats). Plasma noradrenaline concentrations were 1-5 nmol/I on both study days, and plasma atrial natriuretic factor fell from 22-5 to 15 pmol/l. Figure 3 Plots ofleft ventricular end diastolic and end systolic diameters, fractional shortening, and left ventricular mass index immediately before addition of metoprolol 1) and after long term treatment (time 2). Average ventricular dimensions were significantly lower (P < 0 005), fractional shortening significantly greater (P < 0 05) and left ventricular mass significantly reduced (P < 0 05) on follow up. in muscle sympathetic nerve burst freque (r= -0 90, P-0 01; n= 7), muscle syn thetic nerve burst incidence (r = -0 P 0 05; n = 7), and plasma noradrena concentrations (r = -0-76, P -0-08; n between the first and second study. There also a correlation between changes in mu sympathetic nerve activity and changes plasma noradrenaline concentration (r = 0 P-0-06; n = 6) between the first and sec study.
Discussion
Chronic ,B adrenoceptor blockade might b( fit patients with dilated cardiomyopathy antagonising the adverse effects of neui released and circulating catecholamines c adrenergic receptors and on car myocytes,' or by attenuating efferent syn thetic traffic to the heart and peripheral va lature. Attenuation of central sympath outflow should confer greater long term b( fit, since peripheral adrenoceptor bloci leaves a adrenoceptor mediated vasocons tion and renal sodium retention unoppo and the heart and periphery are not shiel from the vasoconstrictor actions of o neurotransmitters coreleased by noradrene nerves, such as neuropeptide Y.23 Morec such generalised sympathoinhibition c( also explain the sustained benefits achieved by the 3,' selective antagonist metoprolol, even though the failing heart has a relatively higher proportion of f21/31 adrenergic receptors than the normal heart.5 6 Activation of the sympathetic nervous system in heart failure has been attributed to impairment of inhibitory afferent input from arterial and cardiopulmonary mechanorecep-"O tors, and recruitment of sympathetic excitatory afferent input from underperfused b skeletal muscle. 3 17 Muscle sympathetic nerve bi burst frequency in patients with heart failure appears to be positively related to pulmonary arterial diastolic pressure, and inversely 2 related to left ventricular stroke work index.24
Consequently, any improvement in these haemodynamic indices might reduce sympathetic outflow reflexively. However, in a substudy of 41 subjects enrolled in the metoprolol in dilated cardiomyopathy trial, those randomised to metoprolol experienced increases in ejection fraction after 12 months of treatment comparable to those of our subjects (from 21% to 34%), as well as increases in cardiac output, yet resting arterial noradrenaline concentrations at that time were no *'
lower than values in the placebo treated group, and net myocardial noradrenaline \ release was similar in placebo and metoprolol treated subjects, both at rest and during exercise.'8 2 There are limitations inherent in this indi-'time rect estimate of sympathetic nerve activity'9 that are exacerbated in heart failure, a condition in which increased noradrenaline concentrations reflect both increased spillover into plasma and decreased regional or total body clearance.2 20 The approach used in the pre-!ncy sent study is fundamentally different: this is apa-the first study in dilated cardiomyopathy to *81, examine directly the effects of long term /3 iline adrenergic blockade with metoprolol on cen-= 6) tral sympathetic outflow to calf muscle, and at was the same time assess a functional consequence Lscle of sympathetic nerve discharge to this bed by s in measuring calf vascular resistance distal to the .-79, recording electrode. Our objective was to test -ond the hypothesis that muscle sympathetic nerve activity diminishes in subjects with dilated cardiomyopathy who improve after long term ,B adrenoceptor blockade. Our principal finding was that efferent postganglionic muscle ene-sympathetic nerve activity decreases in sub-T by jects who respond to long term treatment rally with metoprolol. The subjects in the present )n ,B study had improvement in their symptoms, diac increases in blood pressure, and significant apa-improvement in their left ventricular size and scu-function. There was a 50% reduction in symletic pathetic burst frequency and a 62% reduction ene-in resistance to blood flow in the calf, the rade major muscle bed distal to the recording electric-trode. These changes contrast with the consissed, tency of muscle sympathetic nerve activity Figure 4 Plots of muscle sympathetic burstfrequency, burst incidence, calf vascular resistance, and plasma atrial natriuretic factor concentration immediately before additiot of metoprolol (time 1) and after long term treatment (time 2). There were significant reductions in mean values for muscle sympathetic nerve activity (P < 005), atrial natriuretic factor (P < 005), and calf vascular resistance (P < 0005) between thefirsi and second studies.
improvements in dilated cardiomyopat elicited by adrenergic blockade are n always evident after two to three months Indeed, the results of several short term (1I than three months) placebo controlled dout blind studies of adrenergic blockade thera in congestive heart failure have been disa pointing.222'
The negative chronotropic effect of adrenergic blockade accounts for some of t reduction in muscle sympathetic nerve bu frequency in the present study.'2 The pu synchronous nature of muscle sympathe nerve activity is a consequence of the restrai ing influence of afferent baroreceptor input tonic sympathetic discharge. Since such inp is highest during systole, and virtually abse during diastole, release of this tonic inhibitii during each diastole provides the potential i a subsequent efferent burst. Nonethele chronic /8 adrenergic blockade had an effi on muscle sympathetic nerve burst frequen that was independent of, and in addition 1 its negative chronotropic action, becau burst incidence (burst/100 heart beats) a] fell from pretreatment levels.
Although arising from a single case, dw from the sotolol treated subject are noneti less interesting. If decreased heart rate a increased arterial and cardiac mechanorece tor afferent input were the principal explanation for the effects of ,B adrenoceptor blockade on sympathetic nerve traffic, similar sympathoinhibition should have been observed in this subject. Haemodynamic indices improved, yet burst frequency was 50% higher and burst incidence was 81% higher (and calf vascular resistance distal to the recording electrode 93% higher) on restudy. These discordant findings indicate that mechanisms related to haemodynamic improvement cannot entirely explain the reductions in R muscle sympathetic nerve activity observed after chronic metoprolol treatment in our subjects. Those reductions may result from a 2 drug specific, perhaps central sympathoinhibitory, action of metoprolol.'2
The concordance of neurovascular coupling in these subjects has not been described to date in any group of patients treated for heart failure. Over the short term (five weeks) enalapril causes modest calf vasodilatation (+30%),24 but ACE inhibitors appear to exert this effect through augmentation of endothelial function,25 rather than through sympathob neural withdrawal.26
As the improvement in our subjects' clinical status was temporally related to the addition of metoprolol, which was started because of progressive clinical deterioration despite hospital admission and several months of I treatment, it would be implausible to attribute 2 the haemodynamic and sympathoneural changes in our subjects either to spontaneous n improvement or to a delayed response to their previous drug regimen. Transcardiac and t total body noradrenaline spillover into plasma remain markedly increased despite long term treatment with digitalis, ACE inhibitors, or both.226 Long term placebo controlled trials thy of ,B adrenoceptor blockade in dilated cariot diomyopathy have revealed little or no change 1.0 in haemodynamic variables9 27 or plasma noraess drenaline concentrations'8 28 in placebo ble treated subjects. Because the objective of this py study was to test the hypothesis that muscle ip-sympathetic nerve activity diminishes in subjects with dilated cardiomyopathy who /3 improve after long term treatment with metohe prolol, our principal conclusion, namely that rst efferent postganglionic muscle sympathetic lse nerve activity decreases in those subjects who tic respond to such treatment, remains intact ineven in the absence of a placebo treated on group. The delayed nature of this sympa-)ut thoneural withdrawal'2 may explain why !nt patients do not experience haemodynamic on compromise when exposed to gradually for increasing doses of /l blockade.
ss,
Recently, we have suggested that activation ect of adrenergic drive to the diseased icy myocardium may be a causative mechanism to, linking sympathetic activation to adverse outise come in left ventricular dysfunction, and pro-Iso posed that interventions that selectively modulate sympathetic outflow to the heart ata may benefit such patients, possibly if adminishe-tered early before the development of genernd alised sympathetic activation. The hypothesis !p-that interventions that attenuate sympathetic Rahman, Hara, Daly, Wigle, Floras outflow to the heart will improve outcome in congestive heart failure has not been specifically addressed.3 Because there is concordance between changes in muscle sympathetic nerve activity and cardiac noradrenaline spillover,'9 our present demonstration, by direct microneurographic recordings, that muscle sympathetic nerve activity decreases significantly in patients with idiopathic dilated cardiomyopathy who improve after their conventional therapy is supplemented suggests that metoprolol may be one such intervention. 
